PEER GROUP ANALYSIS
This chart compares IBB to the highest rated funds in its peer group of Sector - Health/Biotechnology funds. The above graph illustrates two key measures that investors should consider when assessing the investment potential of a particular fund. One of the key factors is how the fund has performed over the most recent reporting period, defined as the 1 year total return on the bottom axis. The second factor is the fund's reported expense ratio, on the right axis, which includes things like management fees. The best funds, with higher returns and lower expenses, stake out a position in the lower left part of this graph.
TOP RATED FUNDS : Sector - Health/Biotechnology
|iShares US HealthCare Providers ETF||IHF||11.49||18.65||24.08||0.45||1|
|First Trust Health Care AlphaDEX||FXH||10.80||24.00||27.78||0.70||2|
|iShares US Pharmaceuticals ETF||IHE||11.09||21.35||27.64||0.45||3|
|Health Care Select Sector SPDR||XLV||10.75||20.54||26.55||0.17||4|
|BlackRock Health Sciences Trust||BME||3.46||18.48||23.91||1.12||5|
|H&Q Healthcare Investors||HQH||3.80||14.92||37.37||1.26||6|
|iShares US Healthcare ETF||IYH||10.37||19.34||26.79||0.45||7|
|Vanguard HealthCare Index ETF||VHT||10.07||20.11||27.02||0.13||8|
|iShares Global Healthcare||IXJ||9.42||18.95||23.09||0.48||9|
|iShares Nasdaq Biotechnology||IBB||10.39||24.74||40.76||0.48||17|
|The above table compares the total return performance and expense ratio of iShares Nasdaq Biotechnology to the top rated funds within the Sector - Health/Biotechnology peer group. iShares Nasdaq Biotechnology ranks number 17 out of 28 Sector - Health/Biotechnology closed-end and exchange-traded funds that we rate.|
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
Latest Stock Upgrades/Downgrades